MAP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3878231	0.79	15/20
SCHEMBL2347447	0.59	15/20
SCHEMBL3877600	0.59	15/20
SCHEMBL3883064	0.59	15/20
SCHEMBL2047230	0.56	15/20
SCHEMBL2348492	0.56	15/20
SCHEMBL2348850	0.54	15/20
SCHEMBL2347973	0.52	15/20
SCHEMBL2351469	0.51	15/20
SCHEMBL2352924	0.51	15/20
SCHEMBL3609940	0.51	15/20
SCHEMBL4329236	0.51	15/20
SCHEMBL2349424	0.50	15/20
L-737126 (SCHEMBL2344264)	0.61	14/20
SCHEMBL2918661	0.54	14/20
SCHEMBL2927238	0.54	14/20
SCHEMBL2924539	0.53	14/20
SCHEMBL2918664	0.53	14/20
SCHEMBL2535538	0.52	14/20
SCHEMBL2928734	0.51	14/20

Clinical trials — most relevant to MAP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation	PHASE4	COMPLETED
Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients	PHASE4	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Neuroprotectant for Hypertensive Intracerebral Hemorrhage	PHASE3	UNKNOWN
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer	PHASE3	COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age	PHASE2	ACTIVE_NOT_RECRUITING
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)	PHASE2	NOT_YET_RECRUITING
Fingolimod in Schizophrenia Patients	PHASE2	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia	PHASE1	UNKNOWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease	nan	RECRUITING
Neurorehabilitation in Patients With Disorders of Consciousness: Multidimensional Ambispective Study on the Impact of Single and Combined Approaches	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury	nan	COMPLETED
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)	nan	RECRUITING
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices	nan	ACTIVE_NOT_RECRUITING
Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis	nan	COMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children	nan	COMPLETED
Evaluation of the Role of Neurodegeneration in Schizophrenia	nan	COMPLETED
Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery	nan	NOT_YET_RECRUITING
Neurofilament Surveillance Project (NSP)	nan	ACTIVE_NOT_RECRUITING
Neurofilament Light Chain Correlation With Severity of Symptoms and Cognitive Decline in Mood Disorders	nan	NOT_YET_RECRUITING
Analysis of Pain and Quality of Life in Patients With Charcot-Marie-Tooth Neuropathy (CMT)	nan	COMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP2 binder may also engage these)

Protein	Name	Similarity
P20357	—	1.000	P20357 →
P15146	—	0.997	P15146 →
RTN4	Reticulon-4	0.992	landscape →
A7MC64	—	0.990	A7MC64 →
Q99P72	—	0.989	Q99P72 →
Q9JK11	—	0.988	Q9JK11 →
Q5H9B9	—	0.987	Q5H9B9 →
Q498L0	—	0.986	Q498L0 →
Q5YCW1	—	0.986	Q5YCW1 →
Q16799	—	0.986	Q16799 →
P36225	—	0.985	P36225 →
Q5S6V2	—	0.985	Q5S6V2 →
Q5TB80	—	0.984	Q5TB80 →
Q6UB99	—	0.984	Q6UB99 →
MAPT	Microtubule-associated protein tau	0.984	landscape →
Q8IZ21	—	0.983	Q8IZ21 →
Q4R3X7	—	0.983	Q4R3X7 →
A2A884	—	0.983	A2A884 →
P19332	—	0.983	P19332 →
Q5YCW0	—	0.983	Q5YCW0 →
Q5YCV9	—	0.983	Q5YCV9 →
Q5VWP3	—	0.982	Q5VWP3 →
Q8CGN4	—	0.982	Q8CGN4 →
PEAK1	Inactive tyrosine-protein kinase PEAK1	0.982	landscape →
O46385	—	0.982	O46385 →
A6NCI8	—	0.981	A6NCI8 →
Q9ES97	—	0.981	Q9ES97 →
Q5SWW4	—	0.980	Q5SWW4 →
Q9P2F5	—	0.980	Q9P2F5 →
P49342	—	0.980	P49342 →